New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCardiogen vs Pentapeptide-18

Cardiogen vs Pentapeptide-18

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cardiogen
Skin & CosmeticAnti-Aging & Longevity
Pentapeptide-18
Summary
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide that mimics the sequence of enkephalin, an endogenous neuropeptide. It acts on neuronal pain receptors in facial muscles to reduce muscle contraction intensity and depth of expression lines, functioning similarly to Argireline (Acetyl Hexapeptide-3) but via a different receptor mechanism.
Half-Life
Short (minutes); gene-regulatory effects persist longer
Not applicable (topical)
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
0.005–0.05% in formulation
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
  • Reduces depth of expression lines (forehead, crow's feet, glabellar)
  • Inhibits acetylcholine release for muscle-relaxing effect
  • Complementary mechanism to Argireline for enhanced anti-wrinkle activity
  • Reversible and well-tolerated
  • No risk of systemic paralysis at cosmetic concentrations
  • Suitable for daily use in serums and creams
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
  • Generally very well-tolerated topically
  • Rare skin sensitivity or mild irritation
  • Theoretical opioid receptor desensitization with very prolonged high-dose use (not documented cosmetically)
Stacks With